Asia Pacific Genotyping Market Forecast to 2031 – Regional Analysis – by Product Type (Instruments, Reagents and Kits, Bioinformatics, and Genotyping Services), Technology (Microarray, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR)

The Asia Pacific genotyping market was valued at US$ 6,489.96 million in 2023 and is expected to reach US$ 35,048.62 million by 2031; it is estimated to record a CAGR of 23.5% from 2023 to 2031.

Expanding Range of Applications Boosts Asia Pacific Genotyping Market

Genotyping holds potential applications in diagnostic research, pharmacogenomics, and agricultural biotechnology. Moreover, this technique is suitable for a variety of plant breeding, forensic, and environmental testing procedures. Pharmaceutical companies are profiting from the availability of polygenic risk scores, substantial genetic databases linked to patient health information, and the sequencing data of clinical trial participants, among other advancements. The Industry Pharmacogenomics Working Group (I-PWG), an association of pharmaceutical companies, is actively involved in pharmacogenomic research. The I-PWG comprises 26member companies that undertake numerous clinical trials annually, collecting DNA samples of study subjects as part of the protocol. With its focus on clinical pharmacogenomics, the I-PWG aims to generate opportunities for pharmaceutical companies in the coming years. In addition to its most frequent use in oncology research, it is also used for PGx studies conducted in non-oncology therapeutic areas such as rare diseases, immunology, and cardiology. A more comprehensive study, involving the NGS of clinical trial samples, allows for an elaborate genomic evaluation of trial participants, revealing both common and rare genetic variations. PGx includes the study of polymorphic differences in the determination of genomic-level drug/xenobiotic effects, drug response and disease susceptibility, and genotype/phenotype relationships.

Genotyping-by-sequencing (GBS) is a new method to locate and genotype SNPs in crop genomes and human genome by using NGS methods. GBS is developed and deployed in sequencing multiple samples by incorporating molecular markers in the process to further enhance NGS applications in giant crop genome sequencing, such as maize and wheat. High-throughput SNPs detected by GBS are widely used in genetic diversity analysis, genome-wide association studies (GWAS), QTL mapping, and genome prediction (GP) in many plant species. NGS technology has transformed modern biology with high throughput and low cost. With remarkable advancements unlocked by NGS technologies, whole-genome sequencing provides ultra-throughput sequences that revolutionize plant genotyping and breeding. Sequencing by synthesis (SBS) and multiplexing greatly enhances the efficiency of the sequence.

Therefore, greater adoption of genotyping in various research areas would eventually lead to a rise in the demand for these techniques, creating significant opportunities in the market.

Asia Pacific Genotyping Market Overview

The genotyping market in Asia Pacific is sub-segmented into India, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. An upsurge in technological advancements, decreasing prices of DNA sequencing, the surge in collaborations (for the development of genomic research) among Asian and Western countries, and the rising prevalence of genetic and other target diseases are among the factors propelling the APAC genotyping market.

Asia Pacific Genotyping Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Genotyping Market Segmentation

The Asia Pacific genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the Asia Pacific genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the Asia Pacific genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the Asia Pacific genotyping market is bifurcated into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the Asia Pacific genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific genotyping market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, XCELRIS GENOMICS, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the Asia Pacific genotyping market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific genotyping market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific genotyping market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific genotyping market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.